This Analyst Recently Issued Research Note On ACADIA Pharmaceuticals Inc. (ACAD)

As of Friday close, ACADIA Pharmaceuticals Inc.’s (NASDAQ:ACAD) stock was up $0.82, moving up 5.12 percent to $16.85. The average number of shares traded per day over the past five days has been 2,243,100 shares. 1 time new highs have been achieved over the past 5 days, with a -$1.03 fall in that time frame. In the last twenty days, the average volume was 1,919,715, while in the previous 50 days, it was 1,710,996.

Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '22.
Small-cap Uranium stocks are booming in 2022! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here. .


Since last month, ACAD stock retreated -31.03%. Shares of the company fell to $15.16 on 05/12/22, the lowest level in the past month. A 52-week high of $28.06 was reached on 04/07/22 after having rallying from a 52-week low of $15.16. Since the beginning of this year, ACAD’s stock price has dropped by -27.81% or -$6.49, and marked a new high 9 times. However, the stock has declined by -39.94% since its 52-week high.

ACADIA Pharmaceuticals Inc. (ACAD) last reported insider trading activity 12 days ago on May 02. DAVIS STEPHEN, the CEO of the company, disposed of 5,483 shares for $18.18 on May 02. It resulted in a $99,691 divestment by the insider. Stankovic Srdjan R. sold 2,865 shares at an average price of $18.18 on May 02. The insider now owns 55,188 shares following the transaction. On May 02, EVP,General Counsel, Secretary KIM AUSTIN D. sold 894 shares at $18.18 apiece. The transaction was valued at $16,255.

Valuation Metrics

The stock’s beta is 0.66. Besides these, the trailing price-to-sales (P/S) ratio of 5.81, the price-to-book (PB) ratio of 6.11.

Financial Health

In the three months ended September 29, ACADIA Pharmaceuticals Inc.’s quick ratio stood at 4.50, while its current ratio was 4.50, showing that the company is able to pay off its debt. On the profitability front, the trailing twelve-month gross margin is 96.60% percent. In the year ended September 29, operating margins totaled -43.90%. Based on annual data, ACAD earned $473.3 million in gross profit and brought in $484.14 million in revenue.

A company’s management is another factor that investors consider when determining the profitability of an investment. In the past year, return on investment (ROI) was -31.60%. Return on equity (ROE) for the past 12 months was -40.50%.

According to the earnings report, the company had a lower net income in the recent quarter than it did in the previous quarter. ACAD’s revenue rose 7.72% to $130.76 million during the quarter, while net income inched up to $115.47 million. While analysts expected ACADIA Pharmaceuticals Inc. to report -$0.26 quarterly earnings, the actual figure was -$0.09 per share, beating the consensus estimate by 65.40%. During the quarter, the company generated -$112.05 million in EBITDA. The liabilities of ACADIA Pharmaceuticals Inc. were 179.45 million at the end of its most recent quarter ended September 29, and its total debt was $65.83 million. The value of shareholders’ equity is $161.43 million.

Technical Picture

This quick technical analysis looks at ACADIA Pharmaceuticals Inc.’s (ACAD) price momentum. With a historical volatility rate of 84.15%, the RSI 9-day stood at 36.91% on 13 May.

With respect to its five-day moving average, the current ACADIA Pharmaceuticals Inc. price is down by -5.76% percent or -$1.03. At present, ACAD shares trade -28.21% below its 20-day simple moving average and -37.80% percent below its 100-day simple moving average. However, the stock is currently trading approximately -30.83% below its SMA50 and -24.41% below its SMA200.

Stochastic coefficient K was 16.67% and Stochastic coefficient D was 10.10%, while ATR was 1.23. Given the Stochastic reading of 31.65% for the 14-day period, the RSI (14) reading has been calculated as 35.94%. As of today, the MACD Oscillator reading stands at -1.48, while the 14-day reading stands at -1.99.

Analyst Ratings

Canaccord Genuity upgraded its rating on ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) to a Buy in a note to investors on March 16, 2022. The analysts firm previously had a Hold rating on the stock.ACADIA Pharmaceuticals Inc. (ACAD) has been rated Overweight by analysts. According to 0 brokerage firms, ACAD is a sell, and 12 firms recommend it is a Hold. There are 0 analysts who say the stock is underweight. A total of 0 analysts rate ACADIA Pharmaceuticals Inc. stock as buy, with 9 recommending it as overweight.

With a median target price of $31.00, the current consensus forecast for the stock is $20.00 – $37.00. Based on these forecasts, analysts predict ACADIA Pharmaceuticals Inc. (ACAD) will achieve an average price target of $28.89.


Please enter your comment!
Please enter your name here

Hot Topics

Related Articles